[A16-73] Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48
Last updated 05.01.2017
Project no.:
A16-73
Commission:
Commission awarded on 23.11.2016 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A16-48 | Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2017-01-05 A G-BA decision was published.